Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance

Stock Information for Kamada Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kamada Ltd.

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
Kamada Announces Planned Transition of Chief Financial Officer
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.